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Maternal Vitamin C treatment for fetal lung development 
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IMPACT STATEMENT:  
• Maternal daily Vitamin C treatment for a month in late gestation in sheep increases the expression 
of genes regulating pathways that are essential for normal fetal lung development.  
• Following late gestation Vitamin C exposure in a healthy pregnancy, an increase in lung gene but 
not protein expression may act as a mechanism to aid in preparation for exposure to the air-
breathing environment after birth.  
• In future, availability/development of compounds with greater anti-oxidant properties than 
Vitamin C or more specific targets at the site of oxidative stress in vivo may translate clinically to 
improve respiratory outcomes in complicated pregnancies at birth.  
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ABSTRACT 
BACKGROUND: In the fetus, the appropriate balance of prooxidants and antioxidants is essential to 
negate detrimental effects of oxidative stress on lung maturation. Antioxidants improve respiratory 
function in postnatal life and adulthood. However, the outcomes and biological mechanisms of 
antioxidant action in the fetal lung are unknown.  
METHODS: We investigated the effect of maternal daily Vitamin C treatment (200mg/kg i.v.) for a 
month in late gestation (105-138d gestation, term ~145d) on molecular regulation of fetal lung 
maturation in sheep. Expression of genes and proteins regulating lung development were quantified 
in fetal lung tissue. The number of surfactant-producing cells was determined by 
immunohistochemistry.  
RESULTS: Maternal Vitamin C treatment increased fetal lung gene expression of the antioxidant 
enzyme SOD-1, hypoxia signaling genes (HIF-2α, HIF-3α, ADM, EGLN-3), genes regulating sodium 
movement (SCNN1-A, SCNN1-B, ATP1-A1, ATP1-B1), surfactant maturation (SFTP-B, ABCA3) and 
airway remodelling (ELN). There was no effect of maternal Vitamin C treatment on expression of 
protein markers evaluated or on the number of surfactant protein-producing cells in fetal lung tissue.  
CONCLUSION: Maternal Vitamin C treatment in the last third of pregnancy in sheep acts at the 
molecular level to increase expression of genes that are important for fetal lung maturation in healthy 
pregnancy. 




Antioxidants play a vital role promoting health by scavenging free radicals and preventing oxidative 
stress (1). Healthy pregnancy itself is associated with a pro-oxidant state leading to increased lipid 
peroxidation (2-4). In addition, there is an increased fetal demand for antioxidants during the rapid 
phase of fetal growth in the last 15% of gestation (5). Therefore, an adequate maternal antioxidant 
defense to protect the fetus from oxidative stress is essential for normal development.  
 
An imbalance between a pro- and antioxidant status is associated with a wide range of pregnancy 
complications, including intrauterine growth restriction, preeclampsia, hypertension, and gestational 
diabetes, as well as with environmental factors, such as maternal smoking, all of which can contribute 
to respiratory complications at birth (1, 3, 6-10). Importantly, it has been suggested that neonatal 
complications like respiratory distress may result from the effects of oxidative stress on the molecular 
regulation of lung maturation in utero (8). Antioxidants have been shown to improve lung function 
in children of mothers who smoked in pregnancy (11) and as a result of supplementation in adulthood 
(12, 13). However, research on the effects of oxidative stress or of antioxidant treatment on fetal lung 
maturation has been scant in either healthy or complicated pregnancy.  
 
In healthy pregnancy, the development of the fetal endogenous antioxidant system in late gestation 
parallels the maturation of several mechanisms that regulate lung development (5). These include the 
maturation of the surfactant system and of processes regulating lung liquid movement with advancing 
gestation, including those triggered by glucocorticoids and by hypoxia (5, 14-16). This is important 
because oxidized surfactant proteins show reduced surface tension and immune regulation that may 
predispose to newborn respiratory distress (17-21). Moreover, the regulation of fetal lung liquid 
reabsorption and the maintenance of the epithelial fluid lining in the lung are both important, as lung 
fluid has a role in the pulmonary defense to oxidative stress at the air-liquid interface (22, 23). 
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Combined, therefore, past data highlight the importance of endogenous antioxidants in normal 
development and protecting the development of molecular pathways that regulate fetal lung 
maturation, thereby enabling the successful transition to air-breathing at birth (1). 
 
However, whether maternal antioxidant supplementation to this endogenous antioxidant defense in 
healthy pregnancy is beneficial or detrimental to the molecular regulation of fetal lung maturation is 
completely unknown.  Therefore, in this study, we tested the hypothesis that maternal treatment with 
the Vitamin C in healthy pregnancy has beneficial effects on the molecular regulation of fetal lung 
maturation. The hypothesis was tested in sheep, as this species has a temporal profile of lung 
maturation similar  to humans (24). Understanding the effect of antioxidants on the fetal lung in 
normal development is an important step towards possible antioxidant therapy to promote fetal lung 





All procedures were approved by the University of Cambridge Ethical Review Board and were 
performed in accordance with the UK Animals (Scientific Procedures) Act 1986. 
 
Surgery and experimental protocol 
At 100 ± 1 days gestation (term, ~145 d), 17 pregnant Welsh mountain ewes carrying singleton 
pregnancies underwent a sterile laparotomy under general anesthesia (1.5-2.0 % isofluorane in 60:40 
O2:N2O) to determine fetal sex and catheterisation of the maternal femoral artery and vein, as 
previously described (25-27). To control for sex differences only male fetuses were included in this 
study (female fetuses were assigned to a postnatal study). At 105 d gestation (when the fetal lung is 
in the canalicular phase of development), ewes were randomly assigned to one of two experimental 
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groups: receiving either daily bolus intravenous Saline (n=8) or Vitamin C (200 mg/kg i.v. daily; 
n=9) between 105-138 d gestation. Vitamin C was chosen for administration in this study due to it 
being a commonly used water soluble antioxidant supplement that can cross the placenta (28) and 
shows powerful antioxidant protection in the offspring (27, 29-31). While vitamin C can be easily 
administered orally daily in humans, the maternal i.v. route was chosen in this study to ensure 
complete and better controlled delivery into the maternal circulation. Maternal blood gases, 
hemoglobin concentration and saturation were recorded during baseline (104 and 105 d), 1 day 
following treatment (106 d) and then as summary averages of the preceding 5 days for 110, 115, 120, 
125, 130 and 135d gestation. Blood gas and acid base values were measured using an ABL5 blood 
gas analyser (Radiometer; Copenhagen, Denmark). Values for percentage saturation of hemoglobin 
with oxygen and for the concentration of hemoglobin in blood were determined using a hemoximeter 
(OSM3; Radiometer) (25, 26). At these time intervals, a maternal blood sample was collected for 
subsequent analysis of Vitamin C concentration in plasma.  
 
Post-mortem and sample collection 
Fetuses were evaluated near-term at 138 d gestation when the lung is in the alveolar stage of 
development similar to human late preterm birth (36-37 week of  gestation; term = 40 weeks (24)). 
All ewes and their fetuses were killed by overdose of sodium pentobarbitone (0.4mL/kg, intravenous 
administration, Pentoject; Animal Ltd, York, UK) and fetuses were delivered by hysterotomy. As the 
fetuses in this study were not catheterized, a fetal umbilical arterial blood sample was taken at post-
mortem for measurement of plasma Vitamin C and cortisol concentrations. Fetal body and organ 
weights were recorded. The tissues generated in this study were part of a programme of work designed 
with a different primary objective (27). This study used the tissues generated to begin to address 
additional important scientific questions retrospectively, thereby making best use of the valuable 
experimental material. This scientific approach is strongly promoted by the UK Home Office 3R 
principle of Replacement, Reduction and Refinement designed to ensure more humane animal 
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research. Consequently, no prospective functional outcomes were performed and the lung tissue 
collected was immersion fixed rather than perfusion fixed. A piece of left fetal lung tissue was snap 
frozen in liquid nitrogen and stored at -80 °C for gene and protein expression analysis. A section of 
right fetal lung tissue was immersion fixed in 4 % paraformaldehyde and processed to paraffin for 
further immunohistochemical analysis.  
 
Maternal blood gas status and maternal and fetal plasma assays  
Plasma concentrations of Vitamin C were measured by a fluorimetric technique using a centrifugal 
analyzer with a fluorescence attachment, according to the method of Vuilleumier and Keck (32), in 
collaboration with the Core Biochemical Assay Laboratory, Cambridge, UK. The inter-assay 
coefficients of variation were 7.9 % at 27.1 µmol/L and 5.0 % at 89.7 µmol/L, the lower limit of 
detection of the assay was 10µmol/L. Plasma cortisol concentrations in fetal blood collected were 
measured using a commercially available ELISA kit (RE52061, IBL international, Germany), 
according to the manufacturer’s guidelines as previously described (15, 25).  
 
Quantification of fetal lung mRNA expression 
RNA was extracted and cDNA synthesized from fetal lung tissue samples (~50 mg; Saline, n=8; 
Vitamin C, n=9) as previously described (15, 33). The expression of target genes (Table 1) regulating 
oxidative stress, antioxidant defenses, hypoxia signaling, glucocorticoid signaling, lung liquid 
secretion and reabsorption (regulated by chloride, sodium and water transport across the pulmonary 
epithelium), surfactant maturation (protein and lipid synthesis) and airway remodelling were 
measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR), as previously 
described (15). The abundance of each transcript relative to the abundance of stable reference genes 
(beta-actin, peptidylprolyl isomerase, tyrosine 3-monooxygenase) was calculated using DataAssist 
3.0 analysis software and is expressed as mRNA mean normalized expression (MNE) ± SEM (15). 
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Quantification of fetal lung protein expression 
Protein was extracted by sonication of fetal lung tissue (~100 mg, Saline n=6 and Vitamin C n=7) 
and protein content determined by a MicroBCA Protein Assay Kit (PIERCE, Thermo Fisher 
Scientific Inc., Rockford, Illinois) as previously described (34). Extracted protein samples (75-100 
μg) were subject to sodium dodecyl surface (SDS) page and stained with Coomassie blue to determine 
equal protein loading. Protein samples were transferred onto a 0.45 µm nitrocellulose membrane 
(Hybond ECL, GE HealthCare, NSW, Australia), subjected to one hour of drying at room 
temperature, and then stained with Ponceau S (0.5 % Ponceau in 1 % acetic acid) in order to determine 
the efficacy of the transfer. The membranes were briefly washed with 7 % acetic acid followed by a 
RO water rinse, then imaged for Ponceau S using ImageQuant LAS4000 (GE Healthcare, Victoria, 
Australia). Following imaging, membranes were washed 3 × 5 minutes in tris-buffered saline (TBS). 
The membranes were blocked in 5 % BSA in TBS with 1 % Tween 20 (TBS-T) for 1 hour at room 
temperature. The membranes underwent 3 × 5 minutes washes in TBS-T and were incubated with the 
primary antibody overnight at 4 °C (ENAC-β (1:1000, in 5 % BSA in TBS-T, #PA5-77817, 
Invitrogen; 87 kDa band); Na+-K+-ATPase-A1 (1:1000 in 5 % BSA in TBS-T, #MA3-929, 
Invitrogen; 110 kDa), Na+-K+-ATPase-B1 (1:1000 in 5 % BSA in TBS-T, #MA3-930, Thermofisher; 
50 kDa band); 11βHSD-2 (1:1000, in 5 % BSA in TBS-T, #10004303, Cayman Chemical; 44 kDa 
band); SOD-1 (1:1000, in 5 % BSA in TBS-T, #A3854, Sigma Aldrich; 24 kDa band); SP-B (1:1000, 
in 5 % BSA in TBS-T, #WRAB-48604, Seven Hills Bioreagents; 8 kDa band)). The primary 
antibodies were chosen based on genes that changed in response to maternal Vitamin C administration 
in the fetal lung to determine if the transcriptional changes observed translated into protein abundance 
differences. Following incubation with the primary antibody, the blots were washed and incubated 
with the relevant species of Horse Radish Peroxidase labelled secondary IgG antibody for 1 hour at 
room temperature. Enhanced chemiluminescence using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Australia) was used to detect the blots. The Western blot was imaged 
using ImageQuant LAS4000 and the protein abundance was quantified by densitometry using Image 
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quant software (GE Healthcare, Victoria, Australia). Total target protein abundance was then 
normalized to total protein (Ponceau S) or to a reference protein, β-actin (1:10,000 in 5 % BSA in 
TBS-T, ATCB HRP conjugate, #4967, Cell Signaling Technology; 42 kDa band), β-tubulin (1:10,000 
in 5 % BSA in TBS-T, BetaTUBULIN (9F3) HRP conjugate, #5346, Cell Signaling Technology; 55 
kDa band) or COX1V (3E11) (1:10,000 in 5 % BSA in TBS-T, COX1V (3E11) HRP conjugate, 
#5247P, Cell Signaling Technology; 17 kDa band).   
 
Quantification of surfactant producing cells within the fetal lung 
To determine the effect of maternal Vitamin C administration on the surfactant producing capacity 
of the fetal lung at the structural level, immunohistochemistry was performed (Saline, n=6; Vitamin 
C, n=9), using a rabbit anti-human mature surfactant protein B (SP-B) antibody (1:500, WRAB-
48604, Seven Hills Bioreagents, Ohio), as previously described (15). Sections were examined using 
Visiopharm new Computer Assisted Stereological Toolbox (NewCAST) software (Visiopharm, 
Hoersholm, Denmark) and point counting was used to determine the numerical density of SFTP-B 
positive cells present in the alveolar epithelium of fetal lung tissue, as previously described (15, 35).  
 
Statistical analyses 
All statistical analyses were performed using Statistical Package for Social Sciences (SPSS) v20.1 
(Chicago). Values for maternal blood gas status and plasma ascorbic acid concentrations were 
averaged over the sampling period. All data was evaluated for outliers  2 SD from the mean for each 
treatment group. Comparison of maternal Vitamin C concentrations between baseline and end of 
treatment between groups was determined using a Two-Way ANOVA with Tukey post hoc test. All 
other data were compared using the Student’s t-test for unpaired data (Saline vs. Vitamin C). All data 
are presented as mean  SEM. For all comparisons, P<0.05 was considered statistically significant.  
 
 




Maternal and fetal plasma Vitamin C, maternal blood gas status and fetal growth 
Maternal basal arterial plasma Vitamin C concentrations did not differ between groups (38.0+3.9; 
Vitamin C: 43.8+3.3 μmol/L). While maternal arterial plasma Vitamin C levels remained unchanged 
from baseline in control ewes (39.1+4.3 μmol/L), treatment with Vitamin C significantly increased 
Vitamin C plasma concentration in maternal plasma by the end of the experimental period (81.4+12.8 
μmol/L; P<0.05). Plasma levels of Vitamin C measured in the sample taken from the fetal umbilical 
artery at post-mortem were also elevated in fetuses from mothers treated with Vitamin C compared 
to those treated with vehicle (Table 2). There was no significant effect of maternal Vitamin C 
treatment on maternal arterial blood gases, pH or hemoglobin oxygen saturation during the 
experimental period (Table 2). Similarly, there was no significant effect of maternal Vitamin C 
treatment on fetal body weight, ratio of bi-parietal diameter to lower hind limb length, relative brain 
weight or relative lung weight (Table 2). 
 
Expression of genes regulating oxidative stress  
There was no effect of maternal Vitamin C treatment on the fetal lung mRNA expression of the pro-
oxidant genes NOX-4, HMOX-1, NOS-2 or NOS-3 (Table 3). However, maternal Vitamin C treatment 
increased the fetal lung mRNA expression of the antioxidant SOD-1 (Figure 1A), but had no effect 
on the expression of SOD-2, CAT or GPX (Table 3).  
 
 
Expression of genes regulating hypoxia signaling and feedback 
There was increased mRNA expression of HIF-2α and HIF-3α (Figure 1B and C) but no effect on 
HIF-1α or the constitutively expressed HIF-1β subunit (Table 3) in the lung of fetuses following 
maternal Vitamin C treatment compared to the Saline group. There was a significant increase in the 
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expression of the hypoxia responsive gene ADM (Figure 1D) in the Vitamin C group, but no impact 
on the expression of other hypoxia responsive genes evaluated (VEGF, KDM3A or SLC2A1; Table 
3). There was no difference in the lung mRNA expression of the genes coding for the prolyl 
hydroxylase enzyme isoforms, PHD-2 and -1, EGLN-1 or EGLN-2 (Table 3), respectively. However, 
there was increased expression of the gene EGLN-3 coding for the hypoxia signaling feedback factor, 
PHD-3 in the Vitamin C group (Figure 1E). 
 
Plasma cortisol and expression of genes regulating glucocorticoid availability and activity  
There was no significant effect of maternal Vitamin C treatment on fetal plasma cortisol concentration 
at the conclusion of the experiment (Table 2). There was reduced mRNA expression of glucocorticoid 
deactivating enzyme HSD11β-2 in the fetal lung following maternal Vitamin C treatment (Figure 1F). 
There was no effect of maternal Vitamin C on glucocorticoid activating enzyme HSD11β-1 or 
receptors for downstream glucocorticoid signaling in the fetal lung (NR3C1 and NR3C2; Table 3).  
 
Expression of genes regulating fetal lung liquid secretion and reabsorption  
There was no difference in the expression of genes regulating chloride movement (CFTR or CLCN2) 
between the Saline and Vitamin C group (Table 3). However, there was a significant increase in 
expression of genes regulating sodium movement including SCNN1-A, SCNN1-B, ATP1-A1 and 
ATP1-B1 subunits (Figure 2 A-D), but no effect on SCNN1-G mRNA expression (Table 3) in the 
Vitamin C compared to Saline group. There was no difference in mRNA expression of aquaporin 
water transporter genes AQP-1, AQP-3, AQP-4 or AQP-5 in the fetal lung (Table 3).  
 
Expression of genes regulating surfactant maturation and airway remodelling in the fetal lung  
There was an increase in mRNA expression of the surfactant protein marker SFTP-B and the 
surfactant lipid transporter ABCA3 in fetal lungs from the Vitamin C compared to the Saline group 
McGillick et al.      Maternal antioxidant treatment for fetal lung development 13 
 
(Figure 3A and B). However, there was no difference in the mRNA expression of fetal lung SFTP-A, 
SFTP-C, SFTP-D or surfactant phospholipid synthesis gene PCYT1A between groups (Table 3).  
 
Protein expression of genes that changed in response to maternal Vitamin C administration  
Despite changes in gene expression for the panel of markers investigated, there was no significant 
effect of maternal Vitamin C on the expression of proteins (Figure 4) involved in lung liquid 
reabsorption (ENAC-ß, Na-K-ATPase- α1, Na-K-ATPase-ß1), glucocorticoid activity (11ßHSD-2), 
antioxidant status (SOD-1) or surfactant maturation (SP-B). 
 
Markers of structural development in the fetal lung 
There was no effect of maternal Vitamin C treatment on the numerical density of SP-B positive cells 
present in the alveolar epithelium of the fetal lung tissue (Figure 5A-E). There was increased fetal 
lung mRNA expression of ELN (Figure 5F) following maternal Vitamin C treatment; however, there 





The data show that maternal treatment with Vitamin C for a month in late gestation in healthy 
pregnancy in sheep increases the expression of genes regulating antioxidant defenses (SOD-1), 
sodium movement (SCNN1-A, SCNN1-B, ATP1-A1, ATP1-B1), surfactant maturation (SFTP-B and 
ABCA3) and airway remodelling (ELN) in the fetal lung. These effects of maternal Vitamin C 
supplementation occurred in parallel with an increased expression of genes regulating hypoxia 
signaling (HIF-2α, HIF-3α, ADM, EGLN-3). Conversely, there was no effect of maternal Vitamin C 
on fetal plasma cortisol, or on the expression of glucocorticoid receptors in the fetal lung, or on the 
number of surfactant protein-producing cells in fetal lung tissue, or on the expression of protein 
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markers evaluated. Therefore, the data support the hypothesis tested and suggest that maternal 
treatment with Vitamin C in healthy pregnancy in sheep promotes the molecular regulation of fetal 
lung maturation by increasing gene expression via cortisol-independent pathways.  
 
There was a significant effect of maternal Vitamin C treatment on the expression of genes regulating 
hypoxia signaling. This included an increase in the expression of the HIF-a subunit, a key regulator 
of normal fetal lung development (36) and surfactant maturation (15, 37, 38). Due to the relatively 
short half-life of the HIF- protein subunits, we investigated the expression of the HIF- gene and 
of genes with hypoxia responsive elements (HREs) in their promoter region, including ADM and 
EGLN-3. Regulation of hypoxia signaling is controlled by HIF-α subunit stability, which is negatively 
regulated by the prolyl hydroxylase domain (PHD) family of enzymes encoded by the EGLN gene 
(EGLN-1/PHD-2, EGLN-2/PHD-1 and EGLN-3/PHD-3) (16, 39, 40). Following maternal Vitamin C 
treatment, there was evidence for hypoxia signaling feedback by increased EGLN-3 expression. 
Interestingly, there are similar changes in the lung and heart of the chronically hypoxemic and growth 
restricted fetus (15, 16, 37, 38, 41). Therefore, this may be an adaptive mechanism to limit hypoxia 
signaling following exposure to pro-oxidant milieux, such as chronic fetal hypoxia associated with 
complicated pregnancy or the relative hyperoxia at birth in normal pregnancy (42, 43). As Vitamin C 
or ascorbate is a cofactor for the PHD enzyme activity (44), the increased EGLN-3 expression (gene 
encoding PHD-3) suggests that there may also be antioxidant-independent effects of Vitamin C on 
the regulation of hypoxia signaling in the fetal lung in late gestation.  
 
The effect of either endogenous or exogenous antioxidants on the molecular regulation of fetal lung 
liquid movement has not been previously investigated. This study provides evidence for a limited 
effect of maternal Vitamin C treatment on the expression of genes regulating chloride movement, 
which is a molecular regulator of active liquid secretion into the developing lung throughout gestation 
(24, 45). Conversely, there was increased gene expression of subunits regulating sodium movement, 
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which is important in controlling fetal lung liquid active reabsorption before birth and basal regulation 
of liquid movement at the air-liquid interface in the air-breathing lung (24, 46-48). On balance, we 
did not observe a significant effect of maternal Vitamin C treatment on the expression of the panel of 
proteins investigated that play a role in the molecular regulation of lung liquid movement. There was 
a positive effect of maternal Vitamin C on the expression of genes regulating surfactant maturation 
and surfactant lipid transport. Taken together, these data suggest that at the genomic level maternal 
Vitamin C treatment promotes the expression of molecular markers that aid in the transition to air-
breathing at birth: however, these have not translated into significant effects on protein expression. 
The non-coordinate regulation of gene and protein expression observed in this study may be due to 
several possibilities.  For instance, discordant regulation of gene and protein expression may be due 
to differences in post-transcriptomic modification or transcript degradation following fetal exposure 
to antenatal Vitamin C.  Alternatively, it may simply represent that at the time that tissue was collected 
these signals were not being actively translated as the system had already been maximally 
upregulated.  It may be possible that the increased expression of genes in response to maternal 
Vitamin C treatment in late gestation could serve as a cellular pool of resources that could be rapidly 
translated in the event that the function of these pathways was required to be activated in preparation 
for birth.  As there was no effect on the numerical density of surfactant protein-producing cells present 
in the fetal lung, this suggests that the effects of Vitamin C on surfactant maturation are regulated at 
the molecular level in the fetal lung. This study warrants future work to interrogate the specific 
cellular and translational mechanisms of antenatal antioxidant exposure on the fetal lung. While this 
study has focused on understanding the molecular regulation of fetal lung maturation by maternal 
Vitamin C administration for a month in late gestation, the functional physiological consequences of 
Vitamin C exposure on the fetal lung and surfactant function have not been assessed. Other 
antioxidants, such as Trolox (an analogue of Vitamin E), have been investigated in rats to support 
respiratory function in the newborn period by targeting mechanical ventilation-induced oxidative 
stress locally at the diaphragm (49). Therefore, there are many areas of interest to investigate actions 
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of different antioxidants in the fetal, newborn and postnatal lung, which need to explore the timing, 
dose and mechanism of action.    
 
In regards to structural lung maturation, Vitamin C has previously been demonstrated to lead to 
increased collagen expression and extracellular matrix remodeling, a key component of large 
structural airway development (50-52). However, in this study there was no effect of maternal 
Vitamin C treatment on a marker of collagen content. As the maternal Vitamin C treatment was 
initiated in late gestation, past 100 days and in the canalicular phase of fetal lung development, it is 
likely that the majority of large structural airway development had already occurred in the early 
embryonic and pseudoglandular phases. Interestingly, there was increased expression of ELN in the 
fetal lung, which is suggestive of potential alterations to small airway remodeling and/or 
alveolarization at the parenchymal level following exposure to maternal Vitamin C treatment (53). 
While Vitamin C has previously been shown to play a role in extracellular matrix remodeling in an 
emphysema model (52), the effects of vitamin C on proliferation and apoptosis in the fetal lung are 
unknown.  
 
Since a number of fetal lung maturational signals are stimulated by glucocorticoids (33, 54), it was 
important to determine possible effects on fetal plasma cortisol concentrations and on the regulation 
of cortisol bioactivity and availability. Additional data presented in the current study show that 
maternal Vitamin C treatment did not affect fetal plasma cortisol concentration in an umbilical blood 
sample taken at the end of the experiment. However, maternal Vitamin C treatment was associated 
with a fall in HSD11B-2 expression in the fetal lung. While this finding suggests the potential for an 
increase in local glucocorticoid availability in the fetal lung at the gene level (55), there was no 
significant effect of maternal Vitamin C on 11ßHSD-2 protein expression or on the gene expression 
of glucocorticoid receptors (NR2C1 and NR2C2) in the fetal lung. 
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Vitamin C was chosen for administration in this study due to it being a commonly used supplement 
in pregnancy with antioxidant properties (11, 56, 57). However, Vitamin C is a comparatively weak 
antioxidant with limited capacity to compete for superoxide from reacting with nitric oxide in vivo 
(58-60). To compensate, higher concentrations of Vitamin C are required. Therefore, the dose of 
Vitamin C administered in this study was the same as that used in our previous studies validating 
successful antioxidant properties in the sheep fetus in vivo (29), and it approximated 8 times that used 
in previous human clinical studies (56). Clinical studies, such as the VIP and INTAPP clinical trials 
against preeclampsia, reported an increase in the rate of low birth weight and fetal/newborn mortality 
in mothers treated with Vitamin C compared to those treated with placebo (56, 61). Other studies 
have reported that excess Vitamin C can promote kidney stones (62). Therefore, while data in the 
present study was not associated with growth restriction or fetal death and support maturational 
effects of maternal Vitamin C administration on fetal lung maturation at the molecular level in healthy 
pregnancy, we strongly agree that Vitamin C is not the antioxidant of choice for translation to human 
therapy. Future studies should focus on antioxidants of improved human translational potential that 
have greater antioxidant capacity or more targeted effects on the oxidative stress pathway at the 
cellular level, such as the mitochondria-targeted antioxidant MitoQ (63). 
  
There are important limitations to the data presented in this study. First, all fetuses in this study were 
male to control for, but not to address sex differences. While there is evidence that males are more 
vulnerable to respiratory complications at birth, our previous studies have observed no effect of sex 
on expression of surfactant protein markers in the fetal lung at 133d gestation (38). Secondly, the 
tissues generated in this work were part of a programme of research designed with a different primary 
objective.  This was to investigate the effect of maternal treatment with vitamin C on cardiovascular 
outcomes in the offspring (27). The fetuses did not undergo any other additional interventions as part 
of this primary study other than receiving either daily material administration of saline or Vitamin C 
(105-138d GA). This study used the tissues generated to begin to address additional important 
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scientific questions retrospectively, thereby making best use of the valuable experimental material.  
This scientific approach is strongly promoted by the UK Home Office 3R principle of Replacement, 
Reduction and Refinement and it is designed to ensure more humane animal research.  Consequently, 
no prospective functional outcomes were performed and, in this study, lung tissue was immersion 
and not perfusion fixed.  Therefore, a more detailed quantitative investigation of lung structure could 
not be performed. Nevertheless, the significant maturational effects of Vitamin C on the 
transcriptional capacity of the fetal lung in healthy pregnancy determined in the present study, provide 
proof-of-concept that maternal supplementation with Vitamin C may provide benefits in pregnancies 
with inadequate endogenous antioxidant protection against oxidative stress. This may include 
pregnancies at risk of preterm delivery with immature antioxidant defenses to withstand the relative 
hyperoxia of birth (64, 65), or those with depleted antioxidant protection as a result of an increased 
pro-oxidant environment, such as in pregnancies complicated by preeclampsia, asthma, premature 
rupture of membranes, gestational diabetes, maternal smoking or pollution exposure (1, 3, 6, 7, 9, 66, 
67). Therefore, a rich avenue of research will be to design studies with a specific focus on the lung, 
investigating the effects of different antioxidants of greater human translational capacity on fetal lung 
maturation, matched with newborn and longer-term functional outcomes in healthy as well as in sub-
optimal pregnancy, working towards improving respiratory outcomes in babies born from 
complicated pregnancies.  
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TABLES 
Table 1: Evaluation of target genes regulating oxidative stress, hypoxia signaling, glucocorticoid 
signaling, fetal lung liquid movement (controlled by chloride, sodium and water movement), 
surfactant maturation and airway remodelling by quantitative real-time RT-PCR (all primer 
sequences and concentrations previously published (15)). 
 Gene Name Protein Name Function 
Oxidative stress    
Nicotinamide adenine dinucleotide 
phosphate oxidase 
NOX-4 NAPDH oxidase 4 Pro-oxidant marker 
Heme oxygenase-1  HMOX-1 HMOX-1 Pro-oxidant marker 
Inducible nitric oxide synthase  NOS-2 iNOS Pro-oxidant marker 
Endothelial nitric oxide synthase NOS-3 eNOS Pro-oxidant marker 





Catalase CAT CAT Antioxidant marker 
Glutathione peroxidase GPX GPx Antioxidant marker 
Hypoxia signaling     








Major regulator of 
hypoxia signaling 
Vascular endothelial growth factor  VEGF VEGF Hypoxia responsive 
gene  
Adrenomedullin ADM ADM Hypoxia responsive 
gene 
Lysine (K)-specific demethylase 3A  KDM3A JMJD1A Hypoxia responsive 
gene 
Solute carrier family 2 (facilitated glucose 
transporter) member 1 
SLC2A1 GLUT-1 Hypoxia responsive 
gene 
Egl-9 family hypoxia-inducible factor 








Regulator of HIF 
activity and signaling 
Glucocorticoid signaling    
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11β-hydroxysteroid dehydrogenase enzyme -
1  
HSD11B-1 11βHSD-1 Glucocorticoid 
activating enzyme 
isoform 
11β-hydroxysteroid dehydrogenase enzyme -
2 
HSD11B -2 11βHSD-2 Glucorticoid de-
activating enzyme 
isoform 
Glucocorticoid receptor NR3C1 GR Cellular 
glucocorticoid 
receptor 
Mineralocorticoid receptor  NR3C2 MR Cellular 
glucocorticoid 
receptor 
Molecular regulation of lung liquid 
movement 
   
Cystic fibrosis transmembrane conductance 
regulator  
CFTR CFTR Chloride transport 
channel on pulmonary 
epithelium 
Chloride channel voltage-sensitive 2 channel CLCN2 CLC2 Chloride transport 
channel on pulmonary 
epithelium 







channel on pulmonary 
epithelium 





















Surfactant maturation and lipid transport    
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SFTP-D SP-D and surface tension 
regulating  
Phosphate cytidylyltransferase 1, choline, 
alpha 
PCYT1A PCYT1A Surfactant lipid 
synthesis 
ATP-binding cassette, sub-family A (ABC1), 
member 3 
ABCA3 ATP-A3 Surfactant lipid 
transport 
Airway remodelling    
Elastin ELN ELN Structural role in lung 
tissue development 
Collagen type 1 alpha 1 COL1A1 COL Structural role in lung 
tissue development 
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Maternal pH (arbitrary units) 7.50 ± 0.01 7.50 ± 0.02 
Maternal PaCO2 (mmHg) 33.3 ± 0.6 34.0 ± 0.1 
Maternal PaO2 (mmHg) 104.2 ± 1.2 104.2 ± 1.0 
Maternal Hb saturation (%) 103.6 ± 0.2 104 ± 0.2 
Fetal body weight (kg) 3.99 ± 0.14 3.74 ± 0.35 
Fetal ratio of bi-parietal diameter to hind 
limb lower length 
3.69 ± 0.13 3.38 ± 0.12 
Fetal relative brain weight (g/kg) 10.93 ± 0.19 12.34 ± 0.73 
Fetal relative lung weight (g/kg) 26.05 ± 1.49 22.29 ± 1.26 
Cord plasma vitamin C (mol/L) 20.2 ± 1.2  30.1 ± 1.4 * 
Cord plasma cortisol (ng/mL) 17.6 ± 3.0 28.5 ± 6.2 
Data expressed as mean ± SEM. Data were analyzed by the Student’s unpaired t-test. *P<0.05 was 
considered significant. Maternal blood gas results are the average of samples collected during the 
experiential period. The fetal measurements results were collected at post mortem.  
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Table 3. Effect of maternal Vitamin C treatment on expression of genes regulating oxidative stress, 
hypoxia signaling, glucocorticoid signaling, fetal lung liquid movement (controlled by chloride, 





Pro-oxidant markers   
NOX-4 0.005 ± 0.001 0.004 ± 0.001 
HMOX-1 0.029 ± 0.004 0.032 ± 0.003 
NOS-2 0.019 ± 0.001 0.022 ± 0.002 
NOS-3 0.007 ± 0.001 0.006 ± 0.0003 
Antioxidant markers     
SOD-2 0.036 ± 0.004 0.042 ± 0.003 
CAT 0.16 ± 0.01 0.20 ± 0.02 
GPX 0.010 ± 0.002 0.017 ± 0.003 
Hypoxia signaling    
HIF-1 0.038 ± 0.002 0.042 ± 0.003 
HIF-1β 0.036 ± 0.003 0.039 ± 0.002 
VEGF 0.13 ± 0.01 0.16 ± 0.01 
KDM3A 0.053 ± 0.001 0.059 ± 0.003 
SLC2A1 0.011 ± 0.001 0.013 ± 0.001 
EGLN-1 (PHD-2) 0.062 ± 0.003 0.062 ± 0.004 
EGLN-2 (PHD-1) 0.022 ± 0.001 0.022 ± 0.001 
Glucocorticoid signaling   
HSD11B-1 0.006 ± 0.001 0.007 ± 0.0004 
NR3C1 0.15 ± 0.01 0.17 ± 0.01 
NR3C2 0.007 ± 0.001 0.008 ± 0.001 
Chloride transport   
CFTR 0.0040 ± 0.0002 0.0039 ± 0.0004 
CLCN2 0.0034 ± 0.0003 0.0034 ± 0.0003 
Sodium transport   
SCNN1-G 0.008 ± 0.002 0.015 ± 0.003 
Water transport   
AQP-1 0.22 ± 0.01 0.23 ± 0.02 
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AQP-3 0.0013 ± 0.0002 0.0013 ± 0.0002 
AQP-4 0.009 ± 0.002 0.012 ± 0.002 
AQP-5 0.031 ± 0.003 0.038 ± 0.004 
Surfactant maturation and lipid transport   
SFTP-A 0.43 ± 0.06 0.65 ± 0.11 
SFTP-C 3.44 ± 0.40 4.14 ± 0.41 
SFTP-D 0.029 ±0.004 0.036 ± 0.006 
PCYT1A 0.026 ± 0.002 0.024 ± 0.001 
Airway remodelling   
COL1A1 1.44 ± 0.28 1.48 ± 0.23 
Data expressed as mean normalized expression ± SEM. Data were analyzed by the Student’s unpaired 
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FIGURE LEGENDS 
Figure 1. Effect of maternal Vitamin C on expression of genes regulating antioxidant defence 
(SOD-1, A), hypoxia signaling (HIF-2α, B; HIF-3α, C; ADM, D; EGLN-3, E) and 
glucocorticoid availability (HSD11B-2, F) in the lung of the late gestation sheep fetus. Data 
expressed as mRNA mean normalized expression (MNE) ± SEM in Saline (blue bars, n=8) and 
Vitamin C (orange bars, n=9) groups. Data were analyzed by the Student’s unpaired t-test. *P<0.05 
was considered statistically significant.   
 
Figure 2. Effect of maternal Vitamin C administration on expression of genes regulating 
sodium movement (SCNN1-A, A; SCNN1-B, B; ATP1-A1, C; ATP1-B1, D) in the lung of the 
late gestation sheep fetus. Data expressed as mRNA mean normalized expression (MNE) ± SEM 
in Saline (blue bars, n=8) and Vitamin C (orange bars, n=9) groups. Data were analyzed by the 
Student’s unpaired t-test. *P<0.05 was considered statistically significant.   
 
Figure 3. Effect of maternal Vitamin C administration on expression of genes regulating 
surfactant maturation (SFTP-B, A) and surfactant lipid transport (ABCA3, B) in the lung of 
the late gestation sheep fetus. Data expressed as mRNA mean normalized expression (MNE) ± 
SEM in Saline (blue bars, n=8) and Vitamin C (orange bars, n=9) groups. Data were analyzed by 
the Student’s unpaired t-test. *P<0.05 was considered statistically significant.   
 
Figure 4. Protein expression for genes that changed in the fetal lung in response to maternal 
Vitamin C administration. Data presented as normalized protein expression in arbitrary units (AU) 
for ENAC-ß (A; 87 kDa band), Na-K-ATPase α1 (C; 110 kDa band), Na-K-ATPase ß1 (E; 50 kDa 
band), 11ßHSD-2 (G; 44 kDa band), SOD-1 (I; 24 kDa band) and SP-B (K; 8 kDa band) in Saline 
(blue bars) and Vitamin C (orange bars) groups. Data were analyzed by the Student’s unpaired t-
test. P<0.05 was considered statistically significant. Western blot images represent target protein 
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(upper panel) and reference protein (lower panel) for lambs in saline (S) and vitamin C (VC) 
groups. ⊗ = Not included in analysis for this study. Beta actin (ß-actin; B, D, H; 42 kDa band), 
Cytochrome oxidase IV (COXIV; E; 17 kDa band), Ponceau S (J; Total protein) and beta-tubulin (ß-
tubulin; L; 55 kDa band) are obtained from the same gel.  
 
Figure 5. Effect of maternal Vitamin C administration on numerical density of SP-B positive 
cells in the alveolar epithelium of immersion fixed fetal lung tissue (A-E) and expression of 
gene regulating airway remodelling (ELN (F)). Data expressed as mean or mRNA mean 
normalized expression (MNE) ± SEM in Saline (blue bars, n=8) and Vitamin C (orange bars, n=9) 
groups. Data were analyzed by the Student’s unpaired t-test. *P<0.05 was considered statistically 
significant. Micrographs demonstrating no primary antibody negative control (A), 1:500 rabbit 
serum negative control (B), SP-B immunoreactivity (brown intracellular precipitate) in the 
alveolar epithelium of the fetal lung following maternal Saline (C) and Vitamin C (D) 
administration for a month in late gestation. There was no significant effect of maternal Vitamin 
C (orange bar, n=8, E) on the numerical density of SP-B positive cells per mm2 of lung tissue in 
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Figure 1.  
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Figure 5.  
 
